{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T01:35:32Z","timestamp":1778808932277,"version":"3.51.4"},"reference-count":145,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2005,10,20]],"date-time":"2005-10-20T00:00:00Z","timestamp":1129766400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2005,10,20]],"date-time":"2005-10-20T00:00:00Z","timestamp":1129766400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Cancer"],"published-print":{"date-parts":[[2005,11,1]]},"DOI":"10.1038\/nrc1736","type":"journal-article","created":{"date-parts":[[2005,10,20]],"date-time":"2005-10-20T13:19:22Z","timestamp":1129814362000},"page":"876-885","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":906,"title":["Promoting apoptosis as a strategy for cancer drug discovery"],"prefix":"10.1038","volume":"5","author":[{"given":"Stephen W.","family":"Fesik","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2005,10,20]]},"reference":[{"key":"BFnrc1736_CR1","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1126\/science.7878464","volume":"267","author":"CB Thompson","year":"1995","unstructured":"Thompson, C. B. Apoptosis in the pathogenesis and treatment of disease. Science 267, 1456\u20131462 (1995).","journal-title":"Science"},{"key":"BFnrc1736_CR2","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0092-8674(04)00046-7","volume":"116","author":"NN Danial","year":"2004","unstructured":"Danial, N. N. & Korsmeyer, S. J. Cell death: critical control points. Cell 116, 205\u2013219 (2004).","journal-title":"Cell"},{"key":"BFnrc1736_CR3","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","volume":"100","author":"D Hanahan","year":"2000","unstructured":"Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57\u201370 (2000).","journal-title":"Cell"},{"key":"BFnrc1736_CR4","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1038\/35037747","volume":"407","author":"DW Nicholson","year":"2000","unstructured":"Nicholson, D. W. From bench to clinic with apoptosis-based therapeutic agents. Nature 407, 810\u2013816 (2000).","journal-title":"Nature"},{"key":"BFnrc1736_CR5","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0092-8674(00)81874-7","volume":"88","author":"S Nagata","year":"1997","unstructured":"Nagata, S. Apoptosis by death factor. Cell 88, 355\u2013365 (1997).","journal-title":"Cell"},{"key":"BFnrc1736_CR6","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1146\/annurev.cellbio.15.1.269","volume":"15","author":"I Budihardjo","year":"1999","unstructured":"Budihardjo, I., Oliver, H., Lutter, M., Luo, X. & Wang, X. Biochemical pathways of caspase activation during apoptosis. Annu. Rev. Cell Dev. Biol. 15, 269\u2013290 (1999).","journal-title":"Annu. Rev. Cell Dev. Biol."},{"key":"BFnrc1736_CR7","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S0006-2952(02)01148-6","volume":"64","author":"JB Baell","year":"2002","unstructured":"Baell, J. B. & Huang, D. C. S. Prospects for targeting the Bcl-2 family of proteins to develop novel cytotoxic drugs. Biochem. Pharmacol. 64, 851\u2013863 (2002).","journal-title":"Biochem. Pharmacol."},{"key":"BFnrc1736_CR8","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/40901","volume":"388","author":"QL Deveraux","year":"1997","unstructured":"Deveraux, Q. L., Takahashi, R., Salvesen, G. S. & Reed, J. C. X-linked IAP is a direct inhibitor of cell-death proteases. Nature 388, 300\u2013304 (1997).","journal-title":"Nature"},{"key":"BFnrc1736_CR9","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0092-8674(00)00008-8","volume":"102","author":"C Du","year":"2000","unstructured":"Du, C., Fang, M., Li, Y., Li, L. & Wang, X. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 102, 33\u201342 (2000).","journal-title":"Cell"},{"key":"BFnrc1736_CR10","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0092-8674(00)00009-X","volume":"102","author":"AM Verhagen","year":"2000","unstructured":"Verhagen, A. M. et al. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 102, 43\u201353 (2000).","journal-title":"Cell"},{"key":"BFnrc1736_CR11","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/nrc991","volume":"3","author":"P Chene","year":"2003","unstructured":"Chene, P. Inhibiting the p53\u2013MDM2 interaction: an important target for cancer therapy. Nature Rev. Cancer 3, 102\u2013109 (2003).","journal-title":"Nature Rev. Cancer"},{"key":"BFnrc1736_CR12","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/nrc821","volume":"2","author":"A Ashkenazi","year":"2002","unstructured":"Ashkenazi, A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nature Rev. Cancer 2, 420\u2013421 (2002).","journal-title":"Nature Rev. Cancer"},{"key":"BFnrc1736_CR13","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S1097-2765(00)80207-5","volume":"4","author":"SG Hymowitz","year":"1999","unstructured":"Hymowitz, S. G. et al. Triggering cell death: the crystal structure of Apo2L\/TRAIL in a complex with death receptor 5. Mol. Cell 4, 563\u2013571 (1999).","journal-title":"Mol. Cell"},{"key":"BFnrc1736_CR14","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1038\/14935","volume":"6","author":"J Mongkolsapaya","year":"1999","unstructured":"Mongkolsapaya, J. et al. Structure of the TRAIL\u2013DR5 complex reveals mechanisms conferring specificity in apoptotis initiation. Nature Struct. Biol. 6, 1048\u20131053 (1999).","journal-title":"Nature Struct. Biol."},{"key":"BFnrc1736_CR15","doi-asserted-by":"crossref","first-page":"31171","DOI":"10.1074\/jbc.M004414200","volume":"275","author":"SS Cha","year":"2000","unstructured":"Cha, S. S. et al. Crystal structure of TRAIL\u2013DR5 complex identifies a critical role of the unique frame insertion in conferring recognition specificity. J. Biol. Chem. 275, 31171\u201331177 (2000).","journal-title":"J. Biol. Chem."},{"key":"BFnrc1736_CR16","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.coph.2004.02.006","volume":"4","author":"SK Kelley","year":"2004","unstructured":"Kelley, S. K. & Ashkenazi, A. Targeting death receptors in cancer with Apo2L\/TRAIL. Curr. Opin. Pharmacol. 4, 333\u2013339 (2004). A comprehensive review on targeting TRAIL receptors.","journal-title":"Curr. Opin. Pharmacol."},{"key":"BFnrc1736_CR17","doi-asserted-by":"crossref","first-page":"4891","DOI":"10.4049\/jimmunol.166.8.4891","volume":"166","author":"A Chuntharapai","year":"2001","unstructured":"Chuntharapai, A. et al. Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4. J. Immunol. 166, 4891\u20134898 (2001).","journal-title":"J. Immunol."},{"key":"BFnrc1736_CR18","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/91000","volume":"7","author":"K Ichikawa","year":"2001","unstructured":"Ichikawa, K. et al. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nature Med. 7, 954\u2013960 (2001).","journal-title":"Nature Med."},{"key":"BFnrc1736_CR19","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1084\/jem.20031457","volume":"199","author":"K Takeda","year":"2004","unstructured":"Takeda, K. et al. Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy. J. Exp. Med. 199, 437\u2013448 (2004).","journal-title":"J. Exp. Med."},{"key":"BFnrc1736_CR20","doi-asserted-by":"crossref","first-page":"237","DOI":"10.2174\/1389201023378256","volume":"3","author":"LG Presta","year":"2002","unstructured":"Presta, L. G. Engineering antibodies for therapy. Curr. Pharm. Biotechnol. 3, 237\u2013256 (2002).","journal-title":"Curr. Pharm. Biotechnol."},{"key":"BFnrc1736_CR21","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/pros.20126","volume":"62","author":"S Shankar","year":"2005","unstructured":"Shankar, S., Chen, X. & Srivastava, R. K. Effects of sequential treatments with chemotherapeutic drugs followed by TRAIL on prostate cancer in vitro and in vivo. Prostate 62, 165\u2013186 (2005).","journal-title":"Prostate"},{"key":"BFnrc1736_CR22","doi-asserted-by":"crossref","first-page":"S193","DOI":"10.1038\/sj.cdd.4401535","volume":"11","author":"Inoue","year":"2004","unstructured":"Inoue et al. Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies. Cell Death Differ. 11, S193\u2013S206 (2004).","journal-title":"Cell Death Differ."},{"key":"BFnrc1736_CR23","first-page":"5800","volume":"62","author":"T Naka","year":"2002","unstructured":"Naka, T. et al. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients' colon tumors grown in SCID mice. Cancer Res. 62, 5800\u20135806 (2002).","journal-title":"Cancer Res."},{"key":"BFnrc1736_CR24","first-page":"1362","volume":"7","author":"IF Pollack","year":"2001","unstructured":"Pollack, I. F., Erff, M. & Ashkenazi, A. Direct stimulation of apoptotic signaling by soluble Apo2L\/tumor necrosis factor-related apoptosis-inducing ligand leads to selective killing of glioma cells. Clin. Cancer Res. 7, 1362\u20131369 (2001).","journal-title":"Clin. Cancer Res."},{"key":"BFnrc1736_CR25","doi-asserted-by":"crossref","first-page":"4900","DOI":"10.1158\/0008-5472.CAN-04-0408","volume":"64","author":"H Jin","year":"2004","unstructured":"Jin, H. et al. Apo2 ligand\/tumor necrosis factor-related apoptosis-inducing ligand cooperates with chemotherapy to inhibit orthotopic lung tumor growth and improve survival. Cancer Res. 64, 4900\u20134905 (2004).","journal-title":"Cancer Res."},{"key":"BFnrc1736_CR26","first-page":"4713","volume":"63","author":"S Ray","year":"2003","unstructured":"Ray, S. & Almasan, A. Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2 ligand\/tumor necrosis factor-related apoptosis-inducing ligand and CPT-11. Cancer Res. 63, 4713\u20134723 (2003).","journal-title":"Cancer Res."},{"key":"BFnrc1736_CR27","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1182\/blood.V98.3.795","volume":"98","author":"CS Mitsiades","year":"2001","unstructured":"Mitsiades, C. S. et al. TRAIL\/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood 98, 795\u2013804 (2001).","journal-title":"Blood"},{"key":"BFnrc1736_CR28","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1073\/pnas.030545097","volume":"97","author":"AM Chinnaiyan","year":"2000","unstructured":"Chinnaiyan, A. M. et al. Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. Proc. Natl Acad. Sci USA 97, 1754\u20131759 (2000).","journal-title":"Proc. Natl Acad. Sci USA"},{"key":"BFnrc1736_CR29","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1172\/JCI6926","volume":"104","author":"A Ashkenazi","year":"1999","unstructured":"Ashkenazi, A. et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest. 104, 155\u2013162 (1999).","journal-title":"J. Clin. Invest."},{"key":"BFnrc1736_CR30","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0022-3565(24)29298-3","volume":"299","author":"SK Kelley","year":"2001","unstructured":"Kelley, S. K. et al. Preclinical studies to predict the disposition of Apo2L\/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. J. Pharmacol. Exp. Ther. 299, 31\u201338 (2001).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"BFnrc1736_CR31","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/sj.cdd.4401187","volume":"10","author":"HN LeBlanc","year":"2003","unstructured":"LeBlanc, H. N. & Ashkenazi, A. Apo2L\/TRAIL and its death and decoy receptors. Cell Death Differ. 10, 66\u201375 (2003).","journal-title":"Cell Death Differ."},{"key":"BFnrc1736_CR32","doi-asserted-by":"crossref","first-page":"35829","DOI":"10.1074\/jbc.M405538200","volume":"279","author":"Z Jin","year":"2004","unstructured":"Jin, Z., McDonald III, E. R., Dicker, D. T. & El-Deiry, W. S. Deficient tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor transport to the cell surface in human colon cancer cells selected for resistance to TRAIL-induced apoptosis. J. Biol. Chem. 279, 35829\u201335839 (2004).","journal-title":"J. Biol. Chem."},{"key":"BFnrc1736_CR33","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/sj.cgt.7700747","volume":"11","author":"I Kazhdan","year":"2004","unstructured":"Kazhdan, I. & Marciniak, R. A. Death receptor 4 (DR4) efficiently kills breast cancer cells irrespective of their sensitivity to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Cancer Gene Ther. 11, 691\u2013698 (2004).","journal-title":"Cancer Gene Ther."},{"key":"BFnrc1736_CR34","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1038\/sj.cdd.4401416","volume":"11","author":"M Chawla-Sarkar","year":"2004","unstructured":"Chawla-Sarkar, M. et al. Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L\/TRAIL-induced apoptosis. Cell Death Differ. 11, 915\u2013923 (2004).","journal-title":"Cell Death Differ."},{"key":"BFnrc1736_CR35","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/nm735","volume":"8","author":"S Fulda","year":"2002","unstructured":"Fulda, S., Wick, W., Weller, M. & Debatin, K. M. Smac agonists sensitize for Apo2L\/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nature Med. 8, 808\u2013815 (2002).","journal-title":"Nature Med."},{"key":"BFnrc1736_CR36","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/nm0302-274","volume":"8","author":"H LeBlanc","year":"2002","unstructured":"LeBlanc, H. et al. Tumor-cell resistance to death receptor-induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nature Med. 8, 274\u2013281 (2002).","journal-title":"Nature Med."},{"key":"BFnrc1736_CR37","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1101\/gad.949602","volume":"16","author":"Y Deng","year":"2002","unstructured":"Deng, Y., Lin, Y. & Wu, X. TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac\/DIABLO. Genes Dev. 16, 33\u201345 (2002).","journal-title":"Genes Dev."},{"key":"BFnrc1736_CR38","first-page":"1583","volume":"62","author":"R Ravi","year":"2002","unstructured":"Ravi, R. & Bedi, A. Requirement of BAX for TRAIL\/Apo2L-induced apoptosis of colorectal cancers: synergism with sulindac-mediated inhibition of Bcl-xL. Cancer Res. 62, 1583\u20131587 (2002).","journal-title":"Cancer Res."},{"key":"BFnrc1736_CR39","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/S0962-8924(98)01321-X","volume":"8","author":"A Kelekar","year":"1998","unstructured":"Kelekar, A. & Thompson, C. B. Bcl-2 family proteins: the role of the BH3 domain in apoptosis. Trends Cell Biol. 8, 324\u2013330 (1998).","journal-title":"Trends Cell Biol."},{"key":"BFnrc1736_CR40","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0092-8674(00)00187-2","volume":"103","author":"DC Huang","year":"2000","unstructured":"Huang, D. C. & Strasser, A. BH3-only proteins-essential initiators of apoptotic cell death. Cell 103, 839\u2013842 (2000).","journal-title":"Cell"},{"key":"BFnrc1736_CR41","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1126\/science.1059108","volume":"292","author":"MC Wei","year":"2001","unstructured":"Wei, M. C. et al. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 292, 727\u2013730 (2001).","journal-title":"Science"},{"key":"BFnrc1736_CR42","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.bbamcr.2003.08.012","volume":"1644","author":"AM Petros","year":"2004","unstructured":"Petros, A. M., Olejniczak, E. T. & Fesik, S. W. Structural biology of the Bcl-2 family of proteins. Biochim. Biophys. Acta 1644, 83\u201394 (2004).","journal-title":"Biochim. Biophys. Acta"},{"key":"BFnrc1736_CR43","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1126\/science.275.5302.983","volume":"275","author":"M Sattler","year":"1997","unstructured":"Sattler, M. et al. Structure of Bcl-xL\u2013Bak peptide complex: recognition between regulators of apoptosis. Science 275, 983\u2013986 (1997). First structure that defined pro- and anti-apoptotic BCL2 family members interacting with one another.","journal-title":"Science"},{"key":"BFnrc1736_CR44","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1110\/ps.9.12.2528","volume":"9","author":"AM Petros","year":"2000","unstructured":"Petros, A. M. et al. Rationale for Bcl-xL\/Bad peptide complex formation from structure, mutagenesis, and biophysical studies. Protein Sci. 9, 2528\u20132534 (2000).","journal-title":"Protein Sci."},{"key":"BFnrc1736_CR45","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.bbamcr.2003.08.009","volume":"1644","author":"V Kirkin","year":"2004","unstructured":"Kirkin, V., Joos, S. & Zornig, M. The role of Bcl-2 family members in tumorigenesis. Biochim. Biophys. Acta 1644, 229\u2013249 (2004).","journal-title":"Biochim. Biophys. Acta"},{"key":"BFnrc1736_CR46","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1126\/science.6093263","volume":"226","author":"Y Tsujimoto","year":"1984","unstructured":"Tsujimoto, Y., Finger, L. R., Yunis, J., Nowell, P. C. & Croce, C. M. Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science 226, 1097\u20131099 (1984).","journal-title":"Science"},{"key":"BFnrc1736_CR47","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1126\/science.3929382","volume":"229","author":"Y Tsujimoto","year":"1985","unstructured":"Tsujimoto, Y., Gorham, J., Cossman, J., Jaffe, E. & Croce, C. M. The t(14;18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining. Science 229, 1390\u20131393 (1985).","journal-title":"Science"},{"key":"BFnrc1736_CR48","first-page":"1089","volume":"140","author":"P Gaulard","year":"1992","unstructured":"Gaulard, P. et al. Expression of the bcl-2 gene product in follicular lymphoma. Am. J. Pathol. 140, 1089\u20131095 (1992).","journal-title":"Am. J. Pathol."},{"key":"BFnrc1736_CR49","first-page":"1036","volume":"145","author":"JM Ben-Ezra","year":"1994","unstructured":"Ben-Ezra, J. M., Kornstein, M. J., Grimes, M. M. & Krysal, G. Small cell carcinomas of the lung express the Bcl-2 protein. Am. J. Pathol. 145, 1036\u20131040 (1994).","journal-title":"Am. J. Pathol."},{"key":"BFnrc1736_CR50","first-page":"503","volume":"15","author":"M Higashiyama","year":"1995","unstructured":"Higashiyama, M., Doi, O., Kodama, K., Yokouchi, H. & Tateishi, R. High prevalence of bcl-2 oncoprotein expression in small cell lung cancer. Anticancer Res. 15, 503\u2013505 (1995).","journal-title":"Anticancer Res."},{"key":"BFnrc1736_CR51","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1182\/blood.V79.11.2981.2981","volume":"79","author":"M Schena","year":"1992","unstructured":"Schena, M. et al. Growth- and differentiation-associated expression of bcl-2 in B-chronic lymphocytic leukemia cells. Blood 79, 2981\u20132989 (1992).","journal-title":"Blood"},{"key":"BFnrc1736_CR52","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1038\/sj.leu.2401168","volume":"12","author":"N Harada","year":"1998","unstructured":"Harada, N. et al. Expression of Bcl-2 family of proteins in fresh myeloma cells. Leukemia 12, 1817\u20131820 (1998).","journal-title":"Leukemia"},{"key":"BFnrc1736_CR53","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s004030050479","volume":"292","author":"U Leiter","year":"2000","unstructured":"Leiter, U., Schmid, R. M., Kaskel, P., Peter, R. U. & Krahn, G. Antiapoptotic bcl-2 and bcl-xL in advanced malignant melanoma. Arch. Dermatol. Res. 292, 225\u2013232 (2000).","journal-title":"Arch. Dermatol. Res."},{"key":"BFnrc1736_CR54","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1016\/S0022-5347(01)68235-1","volume":"158","author":"H Matsushima","year":"1997","unstructured":"Matsushima, H. et al. Combined analysis with Bcl-2 and p53 immunostaining predicts poorer prognosis in prostatic carcinoma. J. Urol. 158, 2278\u20132283 (1997).","journal-title":"J. Urol."},{"key":"BFnrc1736_CR55","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1093\/ajcp\/110.4.443","volume":"110","author":"AA Keshgegian","year":"1998","unstructured":"Keshgegian, A. A., Johnston, E. & Cnaan, A. Bcl-2 oncoprotein positivity and high MIB-1 (Ki-67) proliferative rate are independent predictive markers for recurrence in prostate carcinoma. Am. J. Clin. Pathol. 110, 443\u2013449 (1998).","journal-title":"Am. J. Clin. Pathol."},{"key":"BFnrc1736_CR56","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/S0959-8049(99)00124-0","volume":"35","author":"Y Mano","year":"1999","unstructured":"Mano, Y. et al. Bcl-2 as a predictor of chemosensitivity and prognosis in primary epithelial ovarian cancer. Eur. J. Cancer 35, 1214\u20131219 (1999).","journal-title":"Eur. J. Cancer"},{"key":"BFnrc1736_CR57","first-page":"556","volume":"19","author":"T Rajkumar","year":"1998","unstructured":"Rajkumar, T. et al. Prognostic significance of Bcl-2 and p53 protein expression in stage IIB and IIIB squamous cell carcinoma of the cervix. Eur. J. Gynaecol. Oncol. 19, 556\u2013560 (1998).","journal-title":"Eur. J. Gynaecol. Oncol."},{"key":"BFnrc1736_CR58","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1016\/S0022-5347(01)62233-X","volume":"160","author":"D Ye","year":"1998","unstructured":"Ye, D. et al. Bcl-2\/bax expression and p53 gene status in human bladder cancer: relationship to early recurrence with intravesical chemotherapy after resection. J. Urol. 160, 2025\u20132028 (1998).","journal-title":"J. Urol."},{"key":"BFnrc1736_CR59","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1159\/000011910","volume":"55","author":"B Nakata","year":"1998","unstructured":"Nakata, B. et al. Predictive value of Bcl-2 and Bax protein expression for chemotherapeutic effect in gastric cancer. A pilot study. Oncology 55, 543\u2013547 (1998).","journal-title":"Oncology"},{"key":"BFnrc1736_CR60","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1097\/00000658-199812000-00009","volume":"228","author":"H Fries","year":"1998","unstructured":"Fries, H. et al. Moderate activation of the apoptosis inhibitor bcl-xL worsens the prognosis in pancreatic cancer. Ann. Surg. 228, 780\u2013787 (1998).","journal-title":"Ann. Surg."},{"key":"BFnrc1736_CR61","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/path.1711770109","volume":"177","author":"P Lipponen","year":"1995","unstructured":"Lipponen, P. et al. Apoptosis suppressing protein bcl-2 is expressed in well-differentiated breast carcinomas with favourable prognosis. J. Pathol. 177, 49\u201355 (1995).","journal-title":"J. Pathol."},{"key":"BFnrc1736_CR62","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1002\/(SICI)1097-0215(19991222)84:6<562::AID-IJC4>3.0.CO;2-0","volume":"84","author":"MG Le","year":"1999","unstructured":"Le, M. G. et al. c-myc, p53 and bcl-2, apoptosis-related genes in infiltrating breast carcinomas: evidence of a link between bcl-2 protein over-expression and a lower risk of metastasis and death in operable patients. Int. J. Cancer 84, 562\u2013567 (1999).","journal-title":"Int. J. Cancer"},{"key":"BFnrc1736_CR63","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1046\/j.1365-2559.1999.00627.x","volume":"34","author":"L Nakopoulou","year":"1999","unstructured":"Nakopoulou, L. et al. bcl-2 protein expression is associated with a prognostically favourable phenotype in breast cancer irrespective of p53 immunostaining. Histopathology 34, 310\u2013319 (1999).","journal-title":"Histopathology"},{"key":"BFnrc1736_CR64","first-page":"1103","volume":"1","author":"FA Sinicrope","year":"1995","unstructured":"Sinicrope, F. A., Hart, J., Michelassi, F. & Lee, J. J. Prognostic value of bcl-2 oncoprotein expression in stage II colon carcinoma. Clin. Cancer Res. 1, 1103\u20131110 (1995).","journal-title":"Clin. Cancer Res."},{"key":"BFnrc1736_CR65","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/bjc.1995.446","volume":"72","author":"D Ofner","year":"1995","unstructured":"Ofner, D. et al. Immunohistochemically detectable bcl-2 expression in colorectal carcinoma: correlation with tumour stage and patient survival. Br. J. Cancer 72, 981\u2013985 (1995).","journal-title":"Br. J. Cancer"},{"key":"BFnrc1736_CR66","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/(SICI)1097-0142(19960115)77:2<255::AID-CNCR6>3.0.CO;2-L","volume":"77","author":"GB Baretton","year":"1996","unstructured":"Baretton, G. B. et al. Apoptosis and immunohistochemical bcl-2 expression in colorectal adenomas and carcinomas. Aspects of carcinogenesis and prognostic significance. Cancer 77, 255\u2013264 (1996).","journal-title":"Cancer"},{"key":"BFnrc1736_CR67","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1046\/j.1365-2559.1999.00743.x","volume":"35","author":"DT Leahy","year":"1999","unstructured":"Leahy, D. T., Mulcahy, H. E., O'Donoghue, D. P. & Parfrey, N. A. bcl-2 protein expression is associated with better prognosis in colorectal cancer. Histopathology 35, 360\u2013367 (1999).","journal-title":"Histopathology"},{"key":"BFnrc1736_CR68","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1006\/bbrc.1993.1377","volume":"192","author":"T Ohmori","year":"1993","unstructured":"Ohmori, T. et al. Apoptosis of lung cancer cells caused by some anti-cancer agents (MMC, CPT-11, ADM) is inhibited by bcl-2. Biochem. Biophys. Res. Commun. 192, 30\u201336 (1993).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"BFnrc1736_CR69","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1182\/blood.V86.5.1903.bloodjournal8651903","volume":"86","author":"AJ Minn","year":"1995","unstructured":"Minn, A. J., Rudin, C. M., Boise, L. H. & Thompson, C. B. Expression of bcl-xL can confer a multidrug resistance phenotype. Blood 86, 1903\u20131910 (1995).","journal-title":"Blood"},{"key":"BFnrc1736_CR70","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s004320050206","volume":"124","author":"Y Harima","year":"1998","unstructured":"Harima, Y. et al. Bax and Bcl-2 expressions predict response to radiotherapy in human cervical cancer. J. Cancer Res. Clin. Oncol. 124, 503\u2013510 (1998).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"BFnrc1736_CR71","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0090-4295(98)00360-4","volume":"52","author":"TJ Mackey","year":"1998","unstructured":"Mackey, T. J., Borkowski, A., Amin, P., Jacobs, S. C. & Kyprianou, N. bcl-2\/bax ratio as a predictive marker for therapeutic response to radiotherapy in patients with prostate cancer. Urology 52, 1085\u20131090 (1998).","journal-title":"Urology"},{"key":"BFnrc1736_CR72","first-page":"6101","volume":"60","author":"SA Amundson","year":"2000","unstructured":"Amundson, S. A. et al. An informatics approach identifying markers of chemosensitivity in human cancer cell lines. Cancer Res. 60, 6101\u20136110 (2000). Support for BCL-X L as a cancer target.","journal-title":"Cancer Res."},{"key":"BFnrc1736_CR73","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1089\/108729002760220798","volume":"12","author":"RJ Klasa","year":"2002","unstructured":"Klasa, R. J., Gillum, A. M., Klem, R. E. & Frankel, S. R. Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment. Antisense Nucleic Acid Drug Dev. 12, 193\u2013213 (2002). Summary of the use of BCL2 antisense in anticancer treatment.","journal-title":"Antisense Nucleic Acid Drug Dev."},{"key":"BFnrc1736_CR74","first-page":"53","volume":"1705","author":"J Cummings","year":"2004","unstructured":"Cummings, J., Ward, T. H., Ranson, M. & Dive, C. Apoptosis pathway-targeted drugs \u2014 from the bench to the clinic. Biochim. Biophys. Acta 1705, 53\u201366 (2004).","journal-title":"Biochim. Biophys. Acta"},{"key":"BFnrc1736_CR75","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1038\/nrc1631","volume":"5","author":"ME Gleave","year":"2005","unstructured":"Gleave, M. E. & Monia, B. P. Antisense therapy for cancer. Nature Rev. Cancer 5, 468\u2013479 (2005).","journal-title":"Nature Rev. Cancer"},{"key":"BFnrc1736_CR76","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/nrd1464","volume":"3","author":"S Frantz","year":"2004","unstructured":"Frantz, S. Lessons learnt from Genasense's failure. Nature Rev. Drug Discov. 3, 542\u2013543 (2004).","journal-title":"Nature Rev. Drug Discov."},{"key":"BFnrc1736_CR77","doi-asserted-by":"crossref","first-page":"197","DOI":"10.2174\/1568009013334160","volume":"1","author":"S Agrawal","year":"2001","unstructured":"Agrawal, S. & Kandimalla, E. R. Antisense and\/or immunostimulatory oligonucleotide therapeutics. Curr. Cancer Drug Targets 1, 197\u2013209 (2001).","journal-title":"Curr. Cancer Drug Targets"},{"key":"BFnrc1736_CR78","first-page":"2547","volume":"6","author":"U Zangemeister-Wittke","year":"2000","unstructured":"Zangemeister-Wittke, U. et al. A novel bispecific antisense oligonucleotide inhibiting both bcl-2 and bcl-XL expression efficiently induces apoptosis in tumor cells. Clin. Cancer Res. 6, 2547\u20132555 (2000).","journal-title":"Clin. Cancer Res."},{"key":"BFnrc1736_CR79","doi-asserted-by":"crossref","first-page":"13298","DOI":"10.1074\/jbc.274.19.13298","volume":"274","author":"EP Holinger","year":"1999","unstructured":"Holinger, E. P., Chittenden, T. & Lutz, R. J. Bak BH3 peptides antagonize Bcl-xL function and induce apoptosis through cytochrome c-independent activation of caspases. J. Biol. Chem. 274, 13298\u201313304 (1999).","journal-title":"J. Biol. Chem."},{"key":"BFnrc1736_CR80","first-page":"1498","volume":"60","author":"JL Wang","year":"2000","unstructured":"Wang, J. L. et al. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 60, 1498\u20131505 (2000).","journal-title":"Cancer Res."},{"key":"BFnrc1736_CR81","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1126\/science.1099191","volume":"305","author":"LD Walensky","year":"2004","unstructured":"Walensky, L. D. et al. Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. Science 305, 1466\u20131470 (2004).","journal-title":"Science"},{"key":"BFnrc1736_CR82","doi-asserted-by":"crossref","first-page":"11838","DOI":"10.1021\/ja026861k","volume":"124","author":"O Kutzki","year":"2002","unstructured":"Kutzki, O. et al. Development of a potent Bcl-xL antagonist based on \u03b1-helix mimicry. J. Am. Chem. Soc. 124, 11838\u201311839 (2002).","journal-title":"J. Am. Chem. Soc."},{"key":"BFnrc1736_CR83","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/35055095","volume":"3","author":"SP Tzung","year":"2001","unstructured":"Tzung, S. P. et al. Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3. Nature Cell Biol. 3, 183\u2013191 (2001).","journal-title":"Nature Cell Biol."},{"key":"BFnrc1736_CR84","doi-asserted-by":"crossref","first-page":"20453","DOI":"10.1074\/jbc.C300138200","volume":"278","author":"SL Chan","year":"2003","unstructured":"Chan, S. L. et al. Identification of chelerythrine as an inhibitor of BclXL function. J. Biol. Chem. 278, 20453\u201320456 (2003).","journal-title":"J. Biol. Chem."},{"key":"BFnrc1736_CR85","doi-asserted-by":"crossref","first-page":"7947","DOI":"10.1158\/0008-5472.CAN-04-0945","volume":"64","author":"PJ Real","year":"2004","unstructured":"Real, P. J. et al. Breast cancer cells can evade apoptosis-mediated selective killing by a novel small molecule inhibitor of Bcl-2. Cancer Res. 64, 7947\u20137953 (2004).","journal-title":"Cancer Res."},{"key":"BFnrc1736_CR86","doi-asserted-by":"crossref","first-page":"7124","DOI":"10.1073\/pnas.97.13.7124","volume":"97","author":"JL Wang","year":"2000","unstructured":"Wang, J. L. et al. Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc. Natl Acad. Sci. USA 97, 7124\u20137129 (2000).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrc1736_CR87","doi-asserted-by":"crossref","first-page":"4259","DOI":"10.1021\/jm030190z","volume":"46","author":"S Kitada","year":"2003","unstructured":"Kitada, S. et al. Discovery, characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte\/leukemia-2 proteins. J. Med. Chem. 46, 4259\u20134264 (2003).","journal-title":"J. Med. Chem."},{"key":"BFnrc1736_CR88","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1476-4598-4-13","volume":"4","author":"RM Mohammad","year":"2005","unstructured":"Mohammad, R. M. et al. Preclinical studies of a nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-X(L) [(\u2013)-gossypol] against diffuse large cell lymphoma. Mol. Cancer Ther. 4, 13\u201321 (2005).","journal-title":"Mol. Cancer Ther."},{"key":"BFnrc1736_CR89","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1476-4598-4-23","volume":"4","author":"CL Oliver","year":"2005","unstructured":"Oliver, C. L. et al. (\u2013)-Gossypol acts directly on the mitochondria to overcome Bcl-2 and Bcl-X(L)-mediated apoptosis resistance. Mol. Cancer Ther. 4, 23\u201331 (2005).","journal-title":"Mol. Cancer Ther."},{"key":"BFnrc1736_CR90","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/35055085","volume":"3","author":"A Degterev","year":"2001","unstructured":"Degterev, A. et al. Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL. Nature Cell Biol. 3, 173\u2013182 (2001).","journal-title":"Nature Cell Biol."},{"key":"BFnrc1736_CR91","doi-asserted-by":"crossref","first-page":"4313","DOI":"10.1021\/jm010016f","volume":"44","author":"IJ Enyedy","year":"2001","unstructured":"Enyedy, I. J. et al. Discovery of small-molecule inhibitors of Bcl-2 through structure-based computer screening. J. Med. Chem. 44, 4313\u20134324 (2001).","journal-title":"J. Med. Chem."},{"key":"BFnrc1736_CR92","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.chembiol.2004.02.020","volume":"11","author":"B Becattini","year":"2004","unstructured":"Becattini, B. et al. Rational design and real time, in-cell detection of the proapoptotic activity of a novel compound targeting Bcl-xL. Chem. Biol. 11, 389\u2013395 (2004).","journal-title":"Chem. Biol."},{"key":"BFnrc1736_CR93","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nature03579","volume":"435","author":"T Oltersdorf","year":"2005","unstructured":"Oltersdorf, T. et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435, 677\u2013681 (2005). Discovery of the most potent BCL2-family inhibitor to date.","journal-title":"Nature"},{"key":"BFnrc1736_CR94","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/44617","volume":"401","author":"C Sun","year":"1999","unstructured":"Sun, C. et al. NMR structure and mutagenesis of the inhibitor-of-apoptosis protein XIAP. Nature 401, 818\u2013822 (1999).","journal-title":"Nature"},{"key":"BFnrc1736_CR95","doi-asserted-by":"crossref","first-page":"7787","DOI":"10.1074\/jbc.273.14.7787","volume":"273","author":"R Takahashi","year":"1998","unstructured":"Takahashi, R. et al. A single BIR domain of XIAP sufficient for inhibiting caspases. J. Biol. Chem. 273, 7787\u20137790 (1998).","journal-title":"J. Biol. Chem."},{"key":"BFnrc1736_CR96","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S0092-8674(01)00274-4","volume":"104","author":"SJ Riedl","year":"2001","unstructured":"Riedl, S. J. et al. Structural basis for the inhibition of caspase-3 by XIAP. Cell 104, 791\u2013800 (2001).","journal-title":"Cell"},{"key":"BFnrc1736_CR97","doi-asserted-by":"crossref","first-page":"33777","DOI":"10.1074\/jbc.M006226200","volume":"275","author":"C Sun","year":"2000","unstructured":"Sun, C. et al. NMR structure and mutagenesis of the third bir domain of the inhibitor of apoptosis protein XIAP. J. Biol. Chem. 275, 33777\u201333781 (2000).","journal-title":"J. Biol. Chem."},{"key":"BFnrc1736_CR98","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1097-2765(03)00054-6","volume":"11","author":"EN Shiozaki","year":"2003","unstructured":"Shiozaki, E. N. et al. Mechanism of XIAP-mediated inhibition of caspase-9. Mol. Cell 11, 519\u2013527 (2003).","journal-title":"Mol. Cell"},{"key":"BFnrc1736_CR99","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1038\/35050006","volume":"408","author":"Z Liu","year":"2000","unstructured":"Liu, Z. et al. Structural basis for binding of smac\/DIABLO to the XIAP bir3 domain. Nature 408, 1004\u20131008 (2000). This reference, with reference 100, describes the structure of the SMAC\u2013XIAP-BIR3 complex used in the design of XIAP antagonists.","journal-title":"Nature"},{"key":"BFnrc1736_CR100","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1038\/35050012","volume":"408","author":"G Wu","year":"2000","unstructured":"Wu, G. et al. Structural basis of IAP recognition by Smac\/DIABLO. Nature 408, 1008\u20131012 (2000).","journal-title":"Nature"},{"key":"BFnrc1736_CR101","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.1038\/sj.onc.1202569","volume":"17","author":"EC LaCasse","year":"1998","unstructured":"LaCasse, E. C., Baird, S., Korneluk, R. G. & MacKenzie, A. E. The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene 17, 3247\u20133259 (1998).","journal-title":"Oncogene"},{"key":"BFnrc1736_CR102","first-page":"2826","volume":"9","author":"Y Hu","year":"2003","unstructured":"Hu, Y. et al. Antisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lung cancer c in vitro and in vivo. Clin. Cancer Res. 9, 2826\u20132836 (2003).","journal-title":"Clin. Cancer Res."},{"key":"BFnrc1736_CR103","doi-asserted-by":"crossref","first-page":"44236","DOI":"10.1074\/jbc.M207578200","volume":"277","author":"CR Arnt","year":"2002","unstructured":"Arnt, C. R., Chiorean, M. V., Heldebrant, M. P. Gores, G. J. & Kaufmann, S. H. Synthetic smac\/DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAP1 in situ. J. Biol. Chem. 277, 44236\u201344243 (2002).","journal-title":"J. Biol. Chem."},{"key":"BFnrc1736_CR104","first-page":"831","volume":"63","author":"L Yang","year":"2003","unstructured":"Yang, L. et al. Predominant suppression of apoptosome by inhibitor of apoptosis protein in non-small cell lung cancer H460 cells: therapeutic effect of a novel polyarginine-conjugated smac peptide. Cancer Res. 63, 831\u2013837 (2003).","journal-title":"Cancer Res."},{"key":"BFnrc1736_CR105","doi-asserted-by":"crossref","first-page":"4147","DOI":"10.1021\/jm0499108","volume":"47","author":"H Sun","year":"2004","unstructured":"Sun, H. et al. Structure-based design, synthesis, and evaluation of conformationally constrained mimetics of the second mitochondria-derived activator of caspase that target the X-linked inhibitor of apoptosis protein\/caspase-9 interaction site. J. Med. Chem. 47, 4147\u20134150 (2004).","journal-title":"J. Med. Chem."},{"key":"BFnrc1736_CR106","doi-asserted-by":"crossref","first-page":"16686","DOI":"10.1021\/ja047438+","volume":"126","author":"H Sun","year":"2004","unstructured":"Sun, H. et al. Structure-based design of potent, conformationally constrained Smac mimetics. J. Am. Chem. Soc. 126, 16686\u201316687 (2004).","journal-title":"J. Am. Chem. Soc."},{"key":"BFnrc1736_CR107","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.bmcl.2004.11.008","volume":"15","author":"H Sun","year":"2005","unstructured":"Sun, H. et al. Structure-based design, synthesis and biochemical testing of novel and potent Smac peptido-mimetics. Bioorg. Med. Chem. Lett. 15, 793\u2013797 (2005).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"BFnrc1736_CR108","doi-asserted-by":"crossref","first-page":"4417","DOI":"10.1021\/jm040037k","volume":"47","author":"T Oost","year":"2004","unstructured":"Oost, T. et al. Discovery of potent antagonists of the antiapoptotic protein XIAP for the treatment of cancer. J. Med. Chem. 47, 4417\u20134426 (2004).","journal-title":"J. Med. Chem."},{"key":"BFnrc1736_CR109","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S1074-5521(03)00157-1","volume":"10","author":"TYH Wu","year":"2003","unstructured":"Wu, T. Y. H., Wagner, K. W., Bursulaya, B., Schultz, P. G. & Deveraux, Q. L. Development and characterization of nonpeptidic small molecule inhibitors of the XIAP\/caspase-3 interaction. Chem. Biol. 10, 759\u2013767 (2003).","journal-title":"Chem. Biol."},{"key":"BFnrc1736_CR110","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1021\/jm030420+","volume":"47","author":"Z Nikolovska-Coleska","year":"2004","unstructured":"Nikolovska-Coleska, Z. et al. Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XIAP through structure-based computational screening of a traditional herbal medicine three-dimensional structure database. J. Med. Chem. 47, 2430\u20132440 (2004).","journal-title":"J. Med. Chem."},{"key":"BFnrc1736_CR111","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1126\/science.1098231","volume":"305","author":"L Li","year":"2004","unstructured":"Li, L. et al. A small molecule smac mimic potentiates TRAIL- and TNF\u03b1-mediated cell death. Science 305, 1471\u20131474 (2004).","journal-title":"Science"},{"key":"BFnrc1736_CR112","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.bmcl.2004.11.010","volume":"15","author":"C Park","year":"2005","unstructured":"Park, C. et al. Non-peptidic small molecule inhibitors of XIAP. Bioorg. Med. Chem. Lett. 15, 771\u2013775 (2005).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"BFnrc1736_CR113","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1535-6108(03)00332-5","volume":"5","author":"AD Schimmer","year":"2004","unstructured":"Schimmer, A. D. et al. Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity. Cancer Cell 5, 25\u201335 (2004).","journal-title":"Cancer Cell"},{"key":"BFnrc1736_CR114","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nm0897-917","volume":"3","author":"G Ambrosini","year":"1997","unstructured":"Ambrosini, G., Adida, C. & Altieri, D. C. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nature Med. 3, 917\u2013921 (1997). The first report of survivin.","journal-title":"Nature Med."},{"key":"BFnrc1736_CR115","doi-asserted-by":"crossref","first-page":"8581","DOI":"10.1038\/sj.onc.1207113","volume":"22","author":"DC Altieri","year":"2003","unstructured":"Altieri, D. C. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 22, 8581\u20138589 (2003).","journal-title":"Oncogene"},{"key":"BFnrc1736_CR116","first-page":"2805","volume":"60","author":"RA Olie","year":"2000","unstructured":"Olie, R. A. et al. A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res. 60, 2805\u20132809 (2000).","journal-title":"Cancer Res."},{"key":"BFnrc1736_CR117","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1073\/pnas.98.2.635","volume":"98","author":"D Grossman","year":"2001","unstructured":"Grossman, D., Kim, P. J., Schechner, J. S. & Altieri, D. C. Inhibition of melanoma tumor growth in vivo by survivin target. Proc. Natl Acad. Sci. USA 98, 635\u2013640 (2001).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrc1736_CR118","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0378-1119(99)00487-4","volume":"242","author":"J Momand","year":"2000","unstructured":"Momand, J., Wu, H. H. & Dasgupta, G. MDM2 \u2014 master regulator of the p53 tumor suppressor protein. Gene 242, 15\u201329 (2000).","journal-title":"Gene"},{"issue":"Suppl","key":"BFnrc1736_CR119","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1016\/S1471-4914(02)02309-2","volume":"8","author":"DP Lane","year":"2002","unstructured":"Lane, D. P. & Lain, S. Therapeutic exploitation of the p53 pathway. Trends Mol. Med. 8 (Suppl.), S38\u2013S42 (2002).","journal-title":"Trends Mol. Med."},{"key":"BFnrc1736_CR120","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1126\/science.274.5289.948","volume":"274","author":"PH Kussie","year":"1996","unstructured":"Kussie, P. H. et al. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 274, 948\u2013953 (1996). Structure of the p53\u2013MDM2 complex used in the design of MDM2 inhibitors.","journal-title":"Science"},{"key":"BFnrc1736_CR121","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1006\/jmbi.1997.1078","volume":"269","author":"A Bottger","year":"1997","unstructured":"Bottger, A. et al. Molecular characterization of the hdm2-p53 interaction. J. Mol. Biol. 269, 744\u2013756 (1997).","journal-title":"J. Mol. Biol."},{"key":"BFnrc1736_CR122","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1021\/bi000930v","volume":"2","author":"R Stoll","year":"2001","unstructured":"Stoll, R. et al. Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53. Biochemistry 2, 336\u2013344 (2001).","journal-title":"Biochemistry"},{"key":"BFnrc1736_CR123","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0304-3835(02)00084-8","volume":"183","author":"J Zhao","year":"2002","unstructured":"Zhao, J. et al. The initial evaluation of non-peptidic small-molecule HDM2 inhibitors based on p53-HDM2 complex structure. Cancer Lett. 183, 69\u201377 (2002).","journal-title":"Cancer Lett."},{"key":"BFnrc1736_CR124","first-page":"554","volume":"123","author":"SJ Duncan","year":"2001","unstructured":"Duncan, S. J. et al. Isolation and structure elucidation of chlorofusin, a novel p53\u2013MDM2 antagonist from a Fusarium sp. J. Med. Chem. Soc. 123, 554\u2013560 (2001).","journal-title":"J. Med. Chem. Soc."},{"key":"BFnrc1736_CR125","doi-asserted-by":"crossref","first-page":"4163","DOI":"10.1021\/jm034182u","volume":"47","author":"PS Galatin","year":"2004","unstructured":"Galatin, P. S. & Abraham, D. J. A nonpeptidic sulfonamide inhibits the p53\u2013mdm2 interaction and activates p53-dependent transcription in mdm2-overexpressing cells. J. Med. Chem. 47, 4163\u20134165 (2004).","journal-title":"J. Med. Chem."},{"key":"BFnrc1736_CR126","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.bmcl.2004.11.009","volume":"15","author":"DJ Parks","year":"2005","unstructured":"Parks D. J. et al. 1,4\u2013Benzodiazepine\u20132,5-diones as small molecule antagonists of the HDM2\u2013p53 interaction: discovery and SAR. Bioorg. Med. Chem. Lett. 15, 765\u2013770 (2005).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"BFnrc1736_CR127","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1126\/science.1092472","volume":"303","author":"LT Vassilev","year":"2004","unstructured":"Vassilev, L. T. et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303, 844\u2013848 (2004). Discovery of the most potent MDM2 inhibitor to date.","journal-title":"Science"},{"key":"BFnrc1736_CR128","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1042\/bst0320393","volume":"32","author":"P Workman","year":"2004","unstructured":"Workman, P. Inhibiting the phosphoinositide 3-kinase pathway for cancer treatment. Biochem. Soc. Trans. 32, 393\u2013396 (2004).","journal-title":"Biochem. Soc. Trans."},{"key":"BFnrc1736_CR129","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0092-8674(00)80405-5","volume":"91","author":"SR Datta","year":"1997","unstructured":"Datta, S. R. et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91, 231\u2013241 (1997).","journal-title":"Cell"},{"key":"BFnrc1736_CR130","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1126\/science.278.5338.687","volume":"278","author":"L del Paso","year":"1997","unstructured":"del Paso, L., Gonzalez-Garcia, M., Page, C., Herrera, R. & Nunez, G. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 278, 687\u2013689 (1997).","journal-title":"Science"},{"key":"BFnrc1736_CR131","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S0960-9822(98)70302-1","volume":"8","author":"P Blume-Jensen","year":"1998","unstructured":"Blume-Jensen, P., Janknecht, R. & Hunter, T. The kit receptor promotes cell survival via activation of PI 3-kinase and subsequent Akt-mediated phosphorylation of Bad on Ser136. Curr. Biol. 8, 779\u2013782 (1998).","journal-title":"Curr. Biol."},{"key":"BFnrc1736_CR132","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1128\/MCB.21.3.893-901.2001","volume":"21","author":"AH Kim","year":"2001","unstructured":"Kim, A. H., Khursigara, G., Sun, X., Franke, T. F. & Chao, M. V. Akt phosphorylates and negatively regulates apoptosis signal-regulating kinase Mol. Cell. Biol. 21, 893\u2013901 (2001).","journal-title":"Mol. Cell. Biol."},{"key":"BFnrc1736_CR133","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/S0092-8674(00)80595-4","volume":"96","author":"A Brunet","year":"1999","unstructured":"Brunet, A. et al. Akt promotes cell survival by phosphorylating and inhibiting a forkhead transcription factor. Cell 96, 857\u2013868 (1999).","journal-title":"Cell"},{"key":"BFnrc1736_CR134","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1007\/s001099900050","volume":"77","author":"GJ Kops","year":"1999","unstructured":"Kops, G. J. & Burgering, B. M. Forkhead transcription factors: new insights into protein kinase B (c-akt) signaling. J. Mol. Med. 77, 656\u2013665 (1999).","journal-title":"J. Mol. Med."},{"key":"BFnrc1736_CR135","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/19328","volume":"398","author":"GJ Kops","year":"1999","unstructured":"Kops, G. J. et al. Direct control of the forkhead transcription factor AFX by protein kinase B. Nature 398, 630\u2013634 (1999).","journal-title":"Nature"},{"key":"BFnrc1736_CR136","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1182\/blood.V98.8.2508","volume":"98","author":"VM Gelfanov","year":"2001","unstructured":"Gelfanov, V. M. et al. Transformation of interleukin-3-dependent cells without participation of Stat5\/bcl-xL: cooperation of akt with raf\/erk leads to p65 nuclear factor \u03baB-mediated antiapoptosis involving c-IAP2. Blood 98, 2508\u20132517 (2001).","journal-title":"Blood"},{"key":"BFnrc1736_CR137","doi-asserted-by":"crossref","first-page":"4511","DOI":"10.1128\/MCB.23.13.4511-4521.2003","volume":"23","author":"A Trencia","year":"2003","unstructured":"Trencia, A. et al. Protein kinase B\/Akt binds and phosphorylates PED\/PEA-15, stabilizing its antiapoptotic action. Mol. Cell. Biol. 23, 4511\u20134521 (2003).","journal-title":"Mol. Cell. Biol."},{"key":"BFnrc1736_CR138","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2174\/1568009043333032","volume":"4","author":"CS Mitsiades","year":"2004","unstructured":"Mitsiades, C. S., Mitsiades, N. & Koutsilieris, M. The akt pathway: molecular targets for anti-cancer drug development. Curr. Cancer Drug Targets 4, 235\u2013256 (2004).","journal-title":"Curr. Cancer Drug Targets"},{"key":"BFnrc1736_CR139","first-page":"205","volume":"7","author":"Y Lu","year":"2003","unstructured":"Lu, Y., Wang, H. & Mills, G. B. Targeting PI3K\u2013akt pathway for cancer therapy. Rev. Clin. Exp. Hematol. 7, 205\u2013228 (2003).","journal-title":"Rev. Clin. Exp. Hematol."},{"key":"BFnrc1736_CR140","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1158\/1535-7163.MCT-05-0005","volume":"4","author":"Y Luo","year":"2005","unstructured":"Luo, Y. et al. Potent and selective inhibitors of akt kinases slow the progression of tumors in vivo. Mol. Cancer Therap. 4, 977\u2013986 (2005).","journal-title":"Mol. Cancer Therap."},{"key":"BFnrc1736_CR141","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1097\/01.cco.0000143964.74936.d1","volume":"16","author":"EK Rowinsky","year":"2004","unstructured":"Rowinsky, E. K. Targeting the molecular target of rapamycin (mTOR). Curr. Opin. Oncol. 16, 564\u2013575 (2004).","journal-title":"Curr. Opin. Oncol."},{"key":"BFnrc1736_CR142","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nrc1361","volume":"4","author":"J Adams","year":"2004","unstructured":"Adams, J. The proteasome: a suitable antineoplastic target. Nature Rev. Cancer 4, 349\u2013360 (2004).","journal-title":"Nature Rev. Cancer"},{"key":"BFnrc1736_CR143","doi-asserted-by":"crossref","first-page":"9696","DOI":"10.1128\/MCB.24.22.9695-9704.2004","volume":"24","author":"A Fribley","year":"2004","unstructured":"Fribley, A., Zeng, Q. & Wang, C. Y. Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinomous cells. Mol. Cell. Biol. 24, 9696\u20139704 (2004).","journal-title":"Mol. Cell. Biol."},{"key":"BFnrc1736_CR144","first-page":"720","volume":"6","author":"JR Burke","year":"2003","unstructured":"Burke, J. R. Targeting I kappa B kinase for the treatment of inflammatory and other disorders. Curr. Opin. Drug Discov. Devel. 6, 720\u2013728 (2003).","journal-title":"Curr. Opin. Drug Discov. Devel."},{"key":"BFnrc1736_CR145","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1182\/blood.V88.3.1052.1052","volume":"88","author":"G-Q Chen","year":"1996","unstructured":"Chen, G. -Q. et al. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR\u03b1\/PML proteins. Blood 88, 1052\u20131061 (1996).","journal-title":"Blood"}],"container-title":["Nature Reviews Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrc1736.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrc1736","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrc1736.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,5]],"date-time":"2025-01-05T02:32:02Z","timestamp":1736044322000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrc1736"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,10,20]]},"references-count":145,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2005,11,1]]}},"alternative-id":["BFnrc1736"],"URL":"https:\/\/doi.org\/10.1038\/nrc1736","relation":{},"ISSN":["1474-175X","1474-1768"],"issn-type":[{"value":"1474-175X","type":"print"},{"value":"1474-1768","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,10,20]]},"assertion":[{"value":"20 October 2005","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Stephen Fesik is an employee of Abbott Laboratories.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}